| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research Communications |
Background: We examined the cholesterol-lowering effects of a proprietary Chinese red-yeast-rice supplement in an American population consuming a diet similar to the American Heart Association Step I diet using a double-blind, placebo-controlled, prospectively randomized 12-wk controlled trial at a university research center.
Objective: We evaluated the lipid-lowering effects of this red-yeast-rice dietary supplement in US adults separate from effects of diet alone.
Design: Eighty-three healthy subjects (46 men and 37 women aged 34–78 y) with hyperlipidemia [total cholesterol, 5.28–8.74 mmol/L (204–338 mg/dL); LDL cholesterol, 3.31–7.16 mmol/L (128–277 mg/dL); triacylglycerol, 0.62–2.78 mmol/L (55–246 mg/dL); and HDL cholesterol 0.78–2.46 mmol/L (30–95 mg/dL)] who were not being treated with lipid-lowering drugs participated. Subjects were treated with red yeast rice (2.4 g/d) or placebo and instructed to consume a diet providing 30% of energy from fat, <10% from saturated fat, and <300 mg cholesterol daily. Main outcome measures were total cholesterol, total triacylglycerol, and HDL and LDL cholesterol measured at weeks 8, 9, 11, and 12.
Results: Total cholesterol concentrations decreased significantly between baseline and 8 wk in the red-yeast-rice–treated group compared with the placebo-treated group [(
± SD) 6.57 ± 0.93 mmol/L (254 ± 36 mg/dL) to 5.38 ± 0.80 mmol/L (208 ± 31 mg/dL); P < 0.001]. LDL cholesterol and total triacylglycerol were also reduced with the supplement. HDL cholesterol did not change significantly.
Conclusions: Red yeast rice significantly reduces total cholesterol, LDL cholesterol, and total triacylglycerol concentrations compared with placebo and provides a new, novel, food-based approach to lowering cholesterol in the general population.
Key Words: Chinese red yeast rice • Monascus purpureus • lipid-lowering rice food • HMG-CoA • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors • dietary supplement • placebo treatment • low-density-lipoprotein cholesterol • high-density-lipoprotein cholesterol • triacylglycerol
This article has been cited by other articles:
|
|
 |
|
  D. J. Becker, R. Y. Gordon, S. C. Halbert, B. French, P. B. Morris, and D. J. Rader Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial Ann Intern Med, June 16, 2009; 150(12): 830 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Roselle, A. Ekatan, J. Tzeng, M. Sapienza, and J. Kocher Symptomatic Hepatitis Associated with the Use of Herbal Red Yeast Rice Ann Intern Med, October 7, 2008; 149(7): 516 - 517. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Ahn, G. Sethi, and B. B. Aggarwal Simvastatin Potentiates TNF-{alpha}-Induced Apoptosis through the Down-Regulation of NF-{kappa}B-Dependent Antiapoptotic Gene Products: Role of I{kappa}B{alpha} Kinase and TGF-beta-Activated Kinase-1 J. Immunol., February 15, 2007; 178(4): 2507 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K Nies, A. A Cymbala, S. L Kasten, D. G Lamprecht, and K. L Olson Complementary and Alternative Therapies for the Management of Dyslipidemia Ann. Pharmacother., November 1, 2006; 40(11): 1984 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Mueller Symptomatic myopathy due to red yeast rice. Ann Intern Med, September 19, 2006; 145(6): 474 - 475. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Lin, T.-C. Li, and M.-M. Lai Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia Eur. J. Endocrinol., November 1, 2005; 153(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H.K. Vogel, S. F. Bolling, R. B. Costello, E. M. Guarneri, M. W. Krucoff, J. C. Longhurst, B. Olshansky, K. R. Pelletier, C. M. Tracy, R. A. Vogel, et al. Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine) J. Am. Coll. Cardiol., July 5, 2005; 46(1): 184 - 221. [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Zhao, L. Liu, Y. C. Cheng, M. H. Shishehbor, M. H. Liu, D. Q. Peng, and Y. L. Li Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart Disease Circulation, August 24, 2004; 110(8): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, S.-P. Zhao, Y.-C. Cheng, and Y.-L. Li Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease Clin. Chem., August 1, 2003; 49(8): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. A. Jenkins, C. W. C. Kendall, A. Marchie, D. A. Faulkner, J. M. W. Wong, R. de Souza, A. Emam, T. L. Parker, E. Vidgen, K. G. Lapsley, et al. Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein JAMA, July 23, 2003; 290(4): 502 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Bell and J. Shabert Nutritional Modulation of Blood Parameters in Type 2 Diabetes The Diabetes Educator, May 1, 2001; 27(3): 368 - 375. [PDF]
|
|
|
|
 |
|
 E. G Bliznakov More on the Chinese red-yeast-rice supplement and its cholesterol-lowering effect Am. J. Clinical Nutrition, January 1, 2000; 71(1): 152 - 152. [Full Text] [PDF]
|
|
|
|
|
|
D. Heber Reply to EG Bliznakov Am. J. Clinical Nutrition, January 1, 2000; 71(1): 153 - 154. [Full Text]
|
|
|
|
|
|
D. Heber Dietary supplement or drug? The case for Cholestin Am. J. Clinical Nutrition, July 1, 1999; 70(1): 106 - 106. [Full Text]
|
|
|
|
|
|
R. Havel Reply to D Heber Am. J. Clinical Nutrition, July 1, 1999; 70(1): 106a - 108. [Full Text]
|
|
|
|
|
|
R. J Havel Dietary supplement or drug? The case of Cholestin Am. J. Clinical Nutrition, February 1, 1999; 69(2): 175 - 176. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
